Butylone
Viewing r1 — May 3, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Butylone (bk-MBDB) is a synthetic stimulant-entactogen of the cathinone class. It is the β-keto structural analog of MBDB and a structural cousin of methylone, shorter-acting and less potent than MDMA. It blocks dopamine reuptake and triggers serotonin release,[1] producing a hybrid of stimulant drive and entactogenic warmth.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
methylone, mephedrone, MDMA +2 moremethylone, mephedrone, MDMA, amphetamine, cocaine show less
First synthesized in 1967, butylone received no pharmacological study and sat unnoticed for nearly four decades. It surfaced on research chemical markets around 2005 and rode the global "bath salts" wave of 2009–2012, which prompted the first formal research. Butylone is now Schedule I in the United States[3] and controlled in most developed nations.
Subjective effects include euphoria, empathogenic warmth, increased energy, and loosened social inhibition. The experience sits between stimulant push and entactogenic openness — social settings draw out warmth and connection, while solitary contexts emphasize wakefulness and drive. Anxiety, rapid heart rate, and residual stimulation are common undesired effects, with fatigue and low mood following afterward.
Butylone carries moderate abuse liability from its dopamine-blocking activity,[4] and two human deaths are documented — one from combined serotonin syndrome,[5] one from intentional overdose.[6] The most dangerous combination is with other serotonin-raising drugs, which can stack into a life-threatening overheating and seizure crisis. No clinical trials exist — what is known comes from lab studies, two fatality reports, and analogy to related cathinones.
History[edit]
Discovery
Butylone was first synthesized in 1967 during a systematic exploration of β-keto phenethylamine analogues.citation needed It is the β-keto version of MBDB, an entactogen related to the compounds Alexander Shulgin studied. No one characterized it pharmacologically for nearly forty years.
Research chemical emergence and formal study
Around 2005, butylone appeared on research chemical markets as bk-MBDB — often as an unlabeled ingredient in "bath salt" mixtures. The global synthetic cathinone wave of 2009–2012 prompted the first formal studies.[7][8][2]
Fatalities and prohibition
Two deaths linked to butylone were reported in 2012.[5][6] Nations moved to control it between 2009 and 2017 — Israel first, the United Kingdom in 2010,[9] and the US last with permanent Schedule I placement in 2017.[3]
The name bk-MBDB follows standard research chemical nomenclature: "bk" marks the β-keto modification, and MBDB names the parent compound. Butylone circulated during the peak "bath salts" era alongside methylone, mephedrone, and MDPV — consistently described as the least distinctive of the group, more often present as an unlabeled adulterant than a product sold under its own name.
Chemistry[edit]
Structural class
Butylone is a synthetic cathinone — a β-keto phenethylamine — with a 3,4-methylenedioxy ring, the same structural feature found in MDMA and MDA that confers serotonergic activity.
The β-keto group separates cathinones from their amphetamine relatives, but butylone still crosses the blood-brain barrier readily.[2][10] It is the β-keto structural analog of MBDB and a close structural cousin of methylone.
Molecular properties
| Molecular formula (free base) | C₁₂H₁₅NO₃ |
| Molecular weight (free base) | 221.25 g/mol |
| Melting point (HCl salt) | 223–228°C |
| LogP | 1.34 |
Pharmacology[edit]
Mechanism of action
Butylone acts on dopamine and serotonin systems in opposite ways. At the DAT, it blocks clearance — dopamine accumulates rather than being forcibly released, similar to cocaine.[1][4] At the SERT, it acts as a releaser, flooding synapses with serotonin the way MDMA does.[1][2]
The dopamine side produces energy and euphoria; the serotonin side produces warmth and prosocial ease. Animal studies confirm both pathways contribute to butylone's behavioral effects.[8]
Pharmacokinetics
No human pharmacokinetic data exist — half-life, bioavailability, and peak levels are all unknown. The 3–5 hour duration estimate comes from user reports and is unverified.safety citation needed Liver processing generates toxic byproducts rather than clearing the drug safely — blocking CYP450 enzymes made cellular damage worse, not better.[11] The parent compound is the most reliable detection marker in urine.[12]
Neuroscience[edit]
Where it acts
Butylone raises dopamine levels in the brain's reward circuit — the pathway from the midbrain to the nucleus accumbens that drives motivation and pleasure. Simultaneously, serotonin floods broadly through post-synaptic receptors, producing the social ease and warmth characteristic of entactogens.[8]
Why it matters
The dopamine side creates wanting — the pull toward the experience. The serotonin side creates liking — actual hedonic warmth and social pleasure. Together they produce less compulsive redosing drive than pure dopamine stimulants, because serotonin provides a natural brake.
Lab studies show butylone damages human neuronal cells through oxidative stress and programmed cell death.[13] Whether this occurs at recreational doses in living brains is unknown.
Whether butylone causes lasting damage to serotonin nerve terminals — as documented for MDMA — has never been tested in living organisms. Whether its two molecular forms differ in reinforcing potential or toxicity is also unstudied. The full comparison between butylone, methylone, and MDMA in the brain remains unmapped.
Subjective Effects[edit]
Butylone produces a hybrid experience — part stimulant drive, part entactogenic warmth. The balance shifts with context. Social settings draw out empathy and connection; solitary or task-focused settings emphasize wakefulness and physical energy. This context-dependence is more pronounced than in dedicated stimulants or classic entactogens.
Compared to MDMA, butylone is shorter-acting, less potent, and shallower in entactogenic depth — with more prominent stimulant push.[4] Relative to methylone, the character is similar but the ceiling is lower. It sits at the lighter end of the methylenedioxy cathinone family.
Effect Grid
At common doses, butylone's dual pharmacology becomes fully apparent. Stimulation is prominent — increased energy, thought acceleration, enhanced motivation — while entactogenic effects manifest as empathy enhancement, emotional warmth, music enhancement, and increased tactile pleasure. Social inhibitions decrease and conversation flows freely.
Physically, moderate tachycardia, pupil dilation, jaw clenching (bruxism), and diaphoresis are typical. Body temperature elevation occurs; dehydration risk increases with physical activity. Peripheral vasoconstriction may produce cool extremities.
Functional impairment is moderate. Sleep is impossible during effects and difficult for 1-2 hours afterward. Total commitment is approximately 4-6 hours including residual stimulation.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Synesthesia
Body high · Spontaneous body sensations · Dehydration sensation · Dry mouth · Insomnia · Pupil dilation · Excessive sweating · Bruxism · Heart rate perception changes · Muscle tension · Physical fatigue · Tactile euphoria · Tingling / electric sensations · Sexual arousal enhancement · Increased urination · Abnormal heartbeat · Headache · Nausea · Dizziness · Trembling · Vibrations / buzzing
Dry mouth · Insomnia · Pupil dilation · Excessive sweating · Bruxism · Heart rate perception changes · Muscle tension · Physical fatigue · Tactile euphoria · Tingling / electric sensations · Sexual arousal enhancement · Increased urination · Headache · Nausea · Dizziness · Trembling · Vibrations / buzzing
Openness enhancement · Motivation enhancement · Analysis enhancement · Motivation suppression · Focus enhancement · Information processing enhancement · Pattern recognition enhancement · Creativity enhancement · Humor enhancement · Language enhancement · Thought organization · Introspection enhancement · Thought deceleration
Focus enhancement · Information processing enhancement · Pattern recognition enhancement · Creativity enhancement · Humor enhancement · Language enhancement · Thought organization · Introspection enhancement · Thought deceleration
Irritability · Anhedonia · Anxiety · Dysphoria · Emotional lability
Emotional lability
Communication enhancement · Craving · Emotional susceptibility · Flow state · Ego inflation
Ego inflation
Timeline
First alerts manifest as subtle mood lift and mild physical restlessness. The wide onset range (15-60 minutes) reflects variability in gastric contents and individual metabolism.
Stimulation builds progressively — heart rate elevates, sociability increases, and the first hints of entactogenic warmth appear. Mild nausea may occur during this transition.
Maximum intensity of combined stimulant and entactogenic effects. Euphoria, empathy enhancement, music appreciation, and physical energy are at their strongest. Cardiovascular effects (tachycardia, mild hypertension) are most pronounced.
Effects plateau at reduced intensity — stimulation persists while entactogenic warmth gradually fades. Redosing urge may emerge as serotonergic satiety diminishes but dopaminergic drive remains.
Gradual return to baseline. Residual stimulation outlasts the empathogenic effects. Mild fatigue, irritability, or low mood may begin as monoamine stores deplete.
Residual effects include low-grade fatigue, mildly depressed mood, and possible difficulty sleeping due to lingering noradrenergic stimulation. Cognitive function is subtly impaired.
⚠ Do not drive or operate machinery until after a full night's sleep following butylone use.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- methylone · mephedrone · MDMA
Toxicity
No lethal dose has been established for butylone in any species.
Acute toxicity
Two human deaths are documented. One involved combined methylone and butylone sold as "Ecstasy," producing fatal serotonin overload — overheating, coma, and cardiovascular collapse within 48 hours.[5] The second was a deliberate overdose in Poland with a blood level of 20 mg/L — far above the sub-1 mg/L concentrations seen in most cathinone-related deaths.[6][14]
Blood concentration does not reliably predict outcome.[15][16] Class-level acute harms include rapid heart rate, high blood pressure, dangerous overheating, and in severe cases muscle breakdown and organ failure.[17][18][19]
Liver toxicity
Butylone damages liver cells in lab studies through oxidative stress and disrupted cellular energy production.[11] When CYP450 enzymes are blocked, toxicity increases — metabolic processing generates toxic byproducts rather than clearing the drug safely.
Neurotoxicity
Butylone kills human neuronal cells in laboratory cultures through oxidative damage and programmed cell death.[13] Whether this occurs at real-world doses in living brains is unknown — no in vivo neurotoxicity studies have been conducted.
Psychological risks
No butylone-specific controlled data exist. Cathinone class surveys report anxiety, paranoia, agitation, and acute psychosis as adverse effects.[20] The documented serotonin syndrome fatality involved severe agitation and coma before cardiovascular collapse.[5]
Butylone's serotonin-releasing activity makes a serotonin-driven emergency the primary acute psychiatric risk — agitation, confusion, and dangerous overheating that can escalate rapidly.
Tolerance and dependence
No human tolerance or dependence studies exist. Animal evidence shows cathinones with DAT activity support self-administration in proportion to potency.[21][22]
Butylone's moderate dopamine-blocking activity predicts moderate reinforcing potential — less compulsive than MDPV or mephedrone, and partially self-limiting through serotonergic activity. Community tolerance timelines are unverified.safety citation needed
Drug interactions
The primary risk is serotonin overload. Butylone releases serotonin; adding other serotonin-active drugs stacks that load. The documented fatality involved combined butylone and methylone ingestion.[5]
High-risk combinations:
- MAOIs (phenelzine, tranylcypromine, moclobemide): block serotonin breakdown; combining with any serotonin releaser is potentially lethal
- SSRIs/SNRIs (fluoxetine, sertraline, venlafaxine): add to serotonin load; some also alter butylone metabolism unpredictably
- Tramadol: serotonin reuptake inhibitor plus opioid activity creates clear serotonin toxicity risksafety citation needed
- Other MDMA analogues and cathinones: additive serotonergic load, as demonstrated in the documented fatality
CYP450 inhibitors increase butylone's liver toxicity in lab studies.[11] Combining with stimulants (amphetamines, cocaine, other cathinones) adds cardiovascular stress — elevated blood pressure, rapid heart rate, and overheating scale with total stimulant load.
Contraindications
No butylone-specific contraindication data exist. The following are inferred from mechanism:
- Heart conditions: stimulant effects (rapid heart rate, elevated blood pressure) pose direct risk to those with pre-existing cardiac disease
- Liver impairment: metabolic processing generates toxic byproducts; impaired liver function may worsen exposure to those byproducts
- Concurrent serotonergic medication: absolute contraindication given documented lethal serotonin syndrome
- Psychiatric conditions: monoamine stimulation may trigger mania, psychosis, or severe anxiety in predisposed individuals
- Pregnancy: no reproductive data exist; stimulant and serotonergic effects pose theoretical fetal risk
- Seizure disorders: cathinones lower seizure threshold through monoaminergic mechanisms
Harm Reduction[edit]
Forms & Identification
Butylone appears as a white to off-white crystalline powder, visually indistinguishable from methylone, ethylone, and other cathinones. Reagent testing alone cannot reliably distinguish between closely related cathinones. Quantitative drug checking services offer the most reliable identification.
Guidelines
- Test every batch with reagent kits and, where available, quantitative drug checking services
- Start with a low dose and wait at least 90 minutes before considering redosing — stacking doses is the most common path to adverse effects
- Eat a light meal 2–3 hours before; avoid dosing on a full or empty stomach
- Stay hydrated with moderate water intake (roughly 250 mL per hour of activity)
- Have a sober companion present, especially for first experiences
- Set a hard redosing limit before the session begins — dopamine-blocking activity creates a redosing urge that feels more justified than it is
- Avoid use on consecutive days; allow at least two weeks between sessions
Set & Setting
Social environments draw out butylone's entactogenic warmth; solitary settings emphasize stimulant drive. Choose the context deliberately. A familiar environment with trusted people reduces anxiety risk. Avoid physically demanding settings — extended dancing or hot venues — where overheating becomes dangerous. Keep water accessible but avoid over-drinking, which carries its own risks with serotonin-releasing compounds.
Aftercare & integration. The stimulant comedown may bring low mood, fatigue, irritability, and disrupted sleep. Prioritize rest — a dark, quiet environment and screen avoidance help. Eat even if appetite is suppressed; light meals with protein and complex carbohydrates support recovery.
If the experience involved strong emotional content — common with serotonin-releasing compounds — allow time to process it. Journaling or conversation with a trusted person within 24–48 hours helps consolidate insights and identify lingering distress. Persistent low mood, anxiety, or disrupted sleep lasting more than a week warrants professional support.
Recovery & Support
Butylone's moderate reinforcing potential means compulsive use patterns are possible, particularly with frequent redosing. If use has become habitual or difficult to control, structured support is available. SAMHSA's National Helpline (1-800-662-4357) provides free, confidential referrals. SMART Recovery and r/StopSpeeding offer peer support relevant to stimulant and cathinone use patterns.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Jaw tension, restlessness, and mild anxiety are unpleasant but not dangerous. Seek immediate help for: chest pain or pressure, seizure, loss of consciousness, skin that feels burning hot through clothing, severe confusion or agitation that cannot be talked down, or blue-grey skin color.
Immediate steps:
- 1. Move the person to a cool, quiet area
- 2. Call emergency services if any red-flag symptoms are present
- 3. If unconscious but breathing, place in the recovery position (on their side, airway clear)
- 4. Cool actively: remove excess clothing, apply cool water to neck, armpits, and groin
- 5. Do NOT induce vomiting; do NOT restrain unless there is immediate danger of self-harm
What to tell the dispatcher: Name the substance (butylone / synthetic cathinone), approximate amount and time of ingestion, and current symptoms. Good Samaritan laws protect callers from prosecution in many jurisdictions.
Legal Status[edit]
Butylone is controlled in most developed nations, scheduled alongside other synthetic cathinones under laws enacted between 2009 and 2017.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Temporary Schedule I effective March 7, 2014; permanent March 1, 2017. DEA code 7541.[23][3] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Effective April 16, 2010 via generic cathinone amendment (S.I. 2010/1207).[9] |
| China | Category I psychotropic substance | Effective September 2010.[9] |
| Israel | Controlled substance | Effective 2009 — earliest known national control.[9] |
| Japan | Designated Substance (Shitei Yakubutsu) | Controlled under designer drug legislation.[9] |
| Norway | Controlled (analog legislation) | Under Derivatbestemmelsen (derivative provisions).[9] |
| Slovakia | Controlled substance | Effective March 1, 2011.[9] |
| Finland | Controlled substance | Effective December 2014.[9] |
| Italy | Table I controlled substance | Listed in national controlled substances table.[9] |
Analog provisions
Before explicit US scheduling in March 2014, butylone fell under the Federal Analogue Act as a structural analog of scheduled cathinones. Several US states acted earlier: Virginia in July 2012, and Kentucky and Vermont in 2012.[9] No EU-wide scheduling decision specific to butylone exists; national cathinone controls apply in individual member states.
Legal status varies by jurisdiction and changes over time. This information is not legal advice. Verify current status before any travel or import.
references
- [1] ^abcSaha K, Li Y, Holy M, Lehner KR, Bukhari MO, Partilla JS, Sandtner W, Sitte HH, Baumann MH (2019) The synthetic cathinones, butylone and pentylone, are stimulants that act as dopamine transporter blockers but 5-HT transporter substrates. — Psychopharmacology doi:10.1007/s00213-018-5075-5
- [2] ^abcdSimmler LD, Buser TA, Donzelli M, et al. (2012) Pharmacological characterization of designer cathinones in vitro — British Journal of Pharmacology doi:10.1111/j.1476-5381.2012.02145.x
- [3]
- [4] ^abcEshleman AJ, Wolfrum KM, Hatfield MG, Johnson RA, Murphy KV, Janowsky A (2013) Substituted methcathinones differ in transporter and receptor interactions — Biochemical Pharmacology doi:10.1016/j.bcp.2013.04.004
- [5]
- [6] ^abcRojek S, Kłys M, Strona M, Maciów M, Kula K (2012) Legal highs--toxicity in the clinical and medico-legal aspect as exemplified by suicide with bk-MBDB administration. — Forensic Science International doi:10.1016/j.forsciint.2012.04.034